A vaccine to prevent infection with human immunodeficiency virus type 1 (HIV-1) should induce potent, broadly neutralizing antibodies(NA). Our preliminary studies of neutralization escape mutants from the MN strain have demonstrated the mutants to be broadly resistant to NA by an as yet undescribed mechanism, and have focused on the relative paucity of information on the mechanisms of escape mutation that may occur in vivo. We propose to further define mechanisms of resistance of HIV-1 to neutralization by the study of neutralization escape mutants that developed in vivo and in vitro. We are in the process of developing and establishing procedures that will be used in this effort. Envelope genes of interest will be copied by polymerase chain reaction(PCR) and cloned into an expression vector. These expression vectors will be used to express envelope antigen in COS7 cells and will be cotransfected into COS7 cells with HIV-gpt to produce pseudovirions capable of a single cycle of infection. Pseudovirions or envelope proteins that appear to represent escape mutants will be evaluated for antigenic reactivity with monoclonal antibodies and human sera, and for cell tropism, CD4 binding, and gpl20- gp4l association properties. We will use these and other methods to address each of the specific aims of this project The genetic basis for escape mutation of the MN strain variants we have developed will be determined, and biological characteristics associated with neutralization resistance of the variants will be studied. We will establish and study additional neutralization escape mutants in vitro from infectious molecular clones of six T cell line tropic and two macrophage tropic strains of HIV-1, including MN, NL4-3, SF2, Z2Z6, NY5, ALA1, NL(SF162), and AD8. The escape mutants will be selected by propagating the viruses at limiting dilutions in the presence of high titered neutralizing human sera. We will also study mutants developed in vivo which will be obtained from participants in the Multicenter AIDS Cohort Study(MACS) and from a cohort that has been studied extensively in our laboratory. Envelope genes in peripheral blood lymphocytes from these individuals will be cloned and studied. Immunological evaluations of escape mutants will include use of sera from human vaccinees, infected non-human primates, and immunized mice. The results of these studies should elucidate the potential mechanisms of antigenic variation of HIV- l, the relationships of these antigenic changes to other biological properties of the envelope glycoproteins, the potential for induction of broadly cross reactive NA by vaccination, and potential reasons for neutralization resistance of primary isolates of HIV-1.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
3R01AI037438-03S1
Application #
2722591
Study Section
AIDS and Related Research Study Section 1 (ARRA)
Project Start
1995-06-01
Project End
1999-05-31
Budget Start
1997-06-01
Budget End
1998-05-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Henry M. Jackson Fdn for the Adv Mil/Med
Department
Type
DUNS #
City
Rockville
State
MD
Country
United States
Zip Code
20817
Defang, Gabriel N; Khetawat, Dimple; Broder, Christopher C et al. (2010) Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine 29:212-20
Quinnan Jr, Gerald V; Yu, Xiao-Fang; Lewis, Mark G et al. (2005) Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol 79:3358-69
Zhang, Peng Fei; Bouma, Peter; Park, Eun Ju et al. (2002) A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 76:644-55
Park, E J; Gorny, M K; Zolla-Pazner, S et al. (2000) A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J Virol 74:4183-91
Park, E J; Quinnan Jr, G V (1999) Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J Virol 73:5707-13
Chabot, D J; Zhang, P F; Quinnan, G V et al. (1999) Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates. J Virol 73:6598-609
Quinnan Jr, G V; Zhang, P F; Fu, D W et al. (1998) Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants. AIDS Res Hum Retroviruses 14:939-49